FSD Pharma Inc. – NASDAQ:HUGE

Add to watchlist

Market closed

Open in 2 days

-40.12%

month

-77.84%

quarter

-89.25%

year

Market Cap	66.67K
Enterprise value	50.16M

P/E	-2.49
EV/Sales	N/A
EV/EBITDA	-2.60
Price/Sales	N/A
Price/Book	2.02
PEG ratio	-0.04
EPS	-0.32

Revenue	N/A
EBITDA	-8.46M
Income	-13.14M
Revenue Q/Q	N/A
Revenue Y/Y	N/A

Profit margin	0%
Oper. margin	0%
Gross margin	0%
EBIT margin	0%
EBITDA margin	N/A

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

FSD Pharma Inc. (NASDAQ:HUGE): Profit margin
Jun 2023	0	-8.41M
Sep 2023	0	-1.13M
Dec 2023	0	-1.69M
Mar 2024	0	-1.89M

FSD Pharma Financials Estimate

Q Y

FSD Pharma Inc. (NASDAQ:HUGE): Analyst Estimates
Dec 2023	0	-1.69M
Mar 2024	0	-1.89M
Sep 2025	2.19M	-1.58M	-72.18%
Dec 2025	2.19M	-1.58M	-72.18%

Analysts Price target
Financials & Ratios estimates

FSD Pharma Inc. (NASDAQ:HUGE): Debt to assets
Jun 2023	21408091	5.85M	27.37%
Sep 2023	18941551	4.19M	22.15%
Dec 2023	17385421	4.54M	26.13%
Mar 2024	15422739	3.91M	25.42%

FSD Pharma Inc. (NASDAQ:HUGE): Cash Flow
Jun 2023	-3.50M	0	-43.11K
Sep 2023	-1.71M	-269.57K	-54.77K
Dec 2023	-888.24K	-566	-32.19K
Mar 2024	-1.96M	-22.04K	566.17K

FSD Pharma alternative data

FSD Pharma Inc. (NASDAQ:HUGE): Employee count
Aug 2023	17
Sep 2023	17
Oct 2023	17
Nov 2023	17
Dec 2023	17
Jan 2024	17
Feb 2024	17
Mar 2024	17
Apr 2024	17
May 2024	17
Jun 2024	17
Jul 2024	17

FSD Pharma
Hedge Funds Holdings Q1 2023

1.00% -0.61%

of HUGE is owned by hedge funds

7 -6

hedge funds hold HUGE stock

387.35K -175.30K

shares is hold by hedge funds

HUGE hedge funds holdings changes

FSD Pharma
Executives

Insider	Age	Since	Compensation
Mr. Zeeshan Saeed (1972) Founder, Pres & Executive Co-Chairman	53		$224,600

FSD Pharma
Latest News

Monday, 25 November 2024
07:00	Quantum BioPharma Previously Known as FSD Pharma (Nasdaq:HUGE) (CSE:HUGE) Invites Shareholders to Come Forward and Join Hands With the Company in the US700M$+ Court Case the Company Has Filed Against CIBC, RBC, and Others for Alleged Spoofing/Stock Price Manipulation	accesswire.com
Friday, 9 August 2024
20:00	FSD Pharma Announces Share Consolidation and Name Change	newsfilecorp.com
10:51	FSD Pharma Is Up 216% Today. What Is Going On With HUGE Stock?	investorplace.com
07:30	FSD Pharma Provides Update on its Investment in Celly Nutrition Corp. Who Secures Additional Financing to Launch unbuzzd(TM) Stick Packs this Month - Created by a World-Class Pharmaceutical Research & Development Team	accesswire.com
Thursday, 25 July 2024
09:20	24/7 Market News Publishes Report Covering Functional Beverage Market, Featuring FSD Pharma	newsfilecorp.com
Tuesday, 23 July 2024
15:34	FSD Pharma Inc. Announces Results of Annual General and Special Meeting of Shareholders	newsfilecorp.com
10:29	24/7 Market News Publishes Report Covering Biotech Developments, Featuring FSD Pharma	newsfilecorp.com
Thursday, 4 July 2024
08:00	FSD Pharma Files Amended and Restated Material Change Report	newsfilecorp.com
Friday, 28 June 2024
17:00	FSD Pharma provides Corporate Update	accesswire.com
07:30	FSD Pharma, Inc. Wins Final Judgment to Confirm Arbitration Award of $3,059,998 Plus Interest Entered Against Dr. Raza Bokhari, Currently Serving as Chairman and CEO of Medicus Pharma Ltd.	accesswire.com
Thursday, 27 June 2024
07:30	FSD Pharma Receives Ethics Committee Approval for a Phase-1 Multiple Ascending Doses Clinical Trial for Lucid-21-302 (Lucid-MS) in Australia	accesswire.com
Thursday, 13 June 2024
07:30	FSD Pharma Enters Into an Exclusive Option Agreement With the University of Southern California To Evaluate Novel Dietary Supplement Technology for unbuzzd(TM) and Other Business Applications	accesswire.com
Tuesday, 4 June 2024
07:30	FSD Pharma Receives Institutional Review Board Approval to Study the Safety and Efficacy of Unbuzzd(TM) in Acute Alcohol Intoxication	accesswire.com
Friday, 31 May 2024
07:30	FSD Pharma, Inc. Wins Petition to Confirm Arbitration Awards Entered Against Dr. Raza Bokhari Totaling Over $3 Million CAD, Plus Interest	accesswire.com
Thursday, 16 May 2024
08:00	FSD Pharma Provides Update on Celly Nu's New Packaging for unbuzzd(TM)	accesswire.com
Tuesday, 7 May 2024
08:30	FSD Pharma Submits a Phase-1 Multiple Ascending Doses Clinical Trial Application for Lucid-21-302 (Lucid-MS) for Ethics Committee Review in Australia	accesswire.com
Tuesday, 30 April 2024
08:33	FSD Pharma Signs Agreement with Applied Science and Performance Institute (ASPI) to Conduct a Clinical Trial in the United States to Assess the Safety and Efficacy of unbuzzd(TM) in an Induced State of Alcohol Intoxication	accesswire.com
Thursday, 25 April 2024
07:47	FSD Pharma Provides Update from Celly Nu's Partnership with Six+One for unbuzzd(TM)	accesswire.com
Monday, 22 April 2024
08:00	FSD Pharma Provides Another Update on Celly Nu's Anticipated Launch of unbuzzd(TM)	accesswire.com
Wednesday, 17 April 2024
08:00	FSD Pharma Expands Investigative Pipeline to Include Potential Weight Loss and Liver Health Formulations and Products	accesswire.com
Monday, 15 April 2024
08:00	FSD Pharma Provides Update on its Investment in Celly Nutrition Corp., a Company Launching a Product that can assist in Expediting Alcohol Metabolism and Faster Recovery from Alcohol Consumption	accesswire.com
Sunday, 7 April 2024
22:55	FSD Pharma Inc. Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency	newsfilecorp.com
Monday, 1 April 2024
22:00	FSD Pharma Announces Filing of Year-End 2023 Results	accesswire.com
Wednesday, 27 March 2024
08:00	FSD Pharma Signs the Agreement With iNGENu CRO To Conduct a Clinical Study To Assess the Safety and Pharmacokinetics of Multiple Ascending Doses of Lucid-21-302 (Lucid-MS) in Healthy Adults	accesswire.com
Tuesday, 5 March 2024
08:00	FSD Pharma Presents Positive Results on First-In-Human Phase-1 study of Lucid-21-302 (Lucid-MS) at Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) 2024 Forum	accesswire.com
Wednesday, 28 February 2024
08:00	FSD Pharma Announces Debt Settlement	accesswire.com
Monday, 26 February 2024
08:00	FSD Pharma Signs Agreement With Ingenu CRO to Conduct a Clinical Trial To Determine the Safety and Efficacy Effects of its Proprietary Blend Beverage unbuzzd(TM)	accesswire.com
Friday, 16 February 2024
19:50	FSD Pharma Announces US ATM Offering	accesswire.com
Tuesday, 15 August 2023
07:30	FSD Pharma Selected to Present its Phase 1 Data on Lucid-MS at MSMilan 2023 – 9th Joint ECTRIMS-ACTRIMS Meeting for October 11-13, 2023	Accesswire
Monday, 8 May 2023
08:50	FSD Pharma to Present at Sidoti Virtual Investor Conference May 10-11	Business Wire

Ideas & Opinions

Seeking Alpha 29 Mar 2021

FSD Pharma Pivots From Cannabis To COVID-19 Treatment

Frequently Asked Questions (FAQ)

When is FSD Pharma's next earnings date?

Unfortunately, FSD Pharma's (HUGE) next earnings date is currently unknown.
Does FSD Pharma pay dividends?

No, FSD Pharma does not pay dividends.
How much money does FSD Pharma make?

FSD Pharma has a market capitalization of 66.67K.
What is FSD Pharma's stock symbol?

FSD Pharma Inc. is traded on the NASDAQ under the ticker symbol "HUGE".
What is FSD Pharma's primary industry?

Company operates in the Healthcare sector and Drug Manufacturers - Specialty & Generic industry.
How do i buy shares of FSD Pharma?

Shares of FSD Pharma can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Who are FSD Pharma's key executives?
FSD Pharma's management team includes the following people:
- Mr. Zeeshan Saeed Founder, Pres & Executive Co-Chairman(age: 53, pay: $224,600)
Is FSD Pharma founder-led company?

Yes, FSD Pharma is a company led by its founder Mr. Zeeshan Saeed.
How many employees does FSD Pharma have?

As Jul 2024, FSD Pharma employs 17 workers.
When FSD Pharma went public?

FSD Pharma Inc. is publicly traded company for more then 7 years since IPO on 8 Jun 2018.
What is FSD Pharma's official website?

The official website for FSD Pharma is fsdpharma.com.
Where are FSD Pharma's headquarters?

FSD Pharma is headquartered at 199 Bay Street, Toronto, ON.
How can i contact FSD Pharma?

FSD Pharma's mailing address is 199 Bay Street, Toronto, ON and company can be reached via phone at +41 68548884.

FSD Pharma Inc.

fsdpharma.com

Exchange:

NASDAQ

Full time employees:

Industry:

Drug Manufacturers - Specialty & Generic

Sector:

Healthcare

FSD Pharma Inc., through its subsidiaries, operates as a pharmaceutical research and development company. Its lead candidate includes FSD-201 that is in the Phase II clinical trial to treat COVID-19 disease. The company also focuses on Lucid-PSYCH, a psychoactive molecule identified for the potential treatment of neuropsychiatric disorders, such as depressive disorder; and Lucid-MS, a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. FSD Pharma Inc. was founded in 1998 and is headquartered in Toronto, Canada.

+41 68548884

199 Bay Street
Toronto, ON M5L 1A9

CIK: 0001771885
ISIN: CA35954B4047
CUSIP: 35954B206